Difference between revisions of "Meglumine antimonite"
From Dog
| Line 1: | Line 1: | ||
Meglumine antimonate is a pentavalent antimonial drug used for treatment of canine [[leishmaniasis]]. | Meglumine antimonate is a pentavalent antimonial drug used for treatment of canine [[leishmaniasis]]. | ||
| − | Recommended dose rate in dogs is | + | This drug may be given alone or in combination with [[allopurinol]]<ref>Miró G ''et al'' (2008) Canine leishmaniosis–new concepts and insights on an expanding zoonosis: Part two. ''Trends Parasitol'' '''24''':371–377</ref>. |
| + | |||
| + | Recommended dose rate in dogs is 100 mg/kg subcutaneously once a day for twenty-eight consecutive days (3.3 mL/10 kg/day)<ref>Valladares JE ''et al'' (1997) Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs. ''Am J Trop Med Hyg'' '''57(4)''':403-406</ref>. | ||
==References== | ==References== | ||
<References/> | <References/> | ||
Latest revision as of 05:10, 26 April 2013
Meglumine antimonate is a pentavalent antimonial drug used for treatment of canine leishmaniasis.
This drug may be given alone or in combination with allopurinol[1].
Recommended dose rate in dogs is 100 mg/kg subcutaneously once a day for twenty-eight consecutive days (3.3 mL/10 kg/day)[2].
References
- ↑ Miró G et al (2008) Canine leishmaniosis–new concepts and insights on an expanding zoonosis: Part two. Trends Parasitol 24:371–377
- ↑ Valladares JE et al (1997) Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs. Am J Trop Med Hyg 57(4):403-406
